Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Acquisitions & DivestmentsChange in CashExchange Rate EffectFree Cash FlowGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash Items
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioLineRx (BLRX) Capital Expenditures: 2023-2024

Historic Capital Expenditures for BioLineRx (BLRX) over the last 2 years, with Dec 2024 value amounting to $112,000.

  • BioLineRx's Capital Expenditures fell 48.15% to $112,000 in Q4 2024 from the same period last year, while for Dec 2024 it was $269,000, marking a year-over-year increase of 131.90%. This contributed to the annual value of $53,000 for FY2024, which is 54.31% down from last year.
  • Latest data reveals that BioLineRx reported Capital Expenditures of $112,000 as of Q4 2024, which was up 514.81% from -$27,000 recorded in Q2 2024.
  • In the past 5 years, BioLineRx's Capital Expenditures registered a high of $216,000 during Q4 2023, and its lowest value of -$67,000 during Q2 2023.
  • Its 2-year average for Capital Expenditures is $24,143, with a median of -$27,000 in 2024.
  • Over the last 5 years, BioLineRx's Capital Expenditures had its largest YoY gain of 59.70% in 2024, and its largest YoY loss of 48.15% in 2024.
  • BioLineRx's Capital Expenditures (Quarterly) stood at $216,000 in 2023, then slumped by 48.15% to $112,000 in 2024.
  • Its Capital Expenditures was $112,000 in Q4 2024, compared to -$27,000 in Q2 2024 and -$32,000 in Q1 2024.